Neko Health Cost: Affordable Longevity Scan or Screening Trap? (2026)

Neko Health cost is the headline because the price sounds disruptive: a one-hour preventive health scan at GBP 299 in the UK, compared with several-thousand-dollar executive health programs and full-body MRI packages.

Vogue Business profiled Neko Health in June 2026 as an “affordable luxury” approach to preventive scans, built by Spotify co-founder Daniel Ek and Hjalmar Nilsonne.¹ Neko’s official UK page lists a one-hour Health Scan at GBP 299, capturing data across skin, heart, blood, metabolic health, and body composition, followed by a clinician consultation.² Its official New York page describes New York City as Neko’s first North American clinic and says the scan is “coming to NYC in 2026,” but it does not publish a New York price.³

The better buyer question is not “Is it cheap?” It is whether a scan-first model gives you clinically useful decisions, or simply more data to interpret later.

This is buyer education, not medical advice.

Quick Answer

Neko Health is best understood as a preventive health scan model, not a complete replacement for a longevity clinic, primary care doctor, or specialist-led screening program.

Its strength is accessibility. A one-hour, GBP 299 scan with same-visit clinician review is very different from a USD 8,000 to USD 12,000 executive health assessment or scan-heavy longevity-clinic membership. Its limitation is the same limitation that applies to every broad screening model: value depends on what happens after a result. A low-cost scan is useful only if abnormal, uncertain, or borderline findings lead to appropriate confirmation, referral, lifestyle change, medication review, or follow-up.

What Does The Neko Health Scan Measure?

Neko’s UK scan page says the visit captures “millions of data points” across skin, heart, blood, and metabolic health in one appointment.² It lists skin and tissue imaging, ECG and arterial analysis, biometric tests, blood biomarkers, and body composition, with body composition being rolled out across clinics between June 22 and July 10, 2026.

Neko also says blood results are ready during the same visit for cholesterol, metabolic health, and immune function; a clinician reviews imaging, body composition, and cardiovascular health; and follow-ups, referral letters, and specialist introductions are included if advised. Results can be shared with a GP through the Neko app.²

That is a meaningful scan package. It is also different from full-body MRI. Neko states that its devices are radiation-free and that it uses no X-rays and no MRI.² Buyers comparing it with full-body MRI at longevity clinics should not treat the two products as interchangeable.

Why The Price Point Matters

Neko’s pricing creates a middle category between ordinary preventive care and premium longevity diagnostics.

At the high end, Human Longevity Inc. positions executive health around dense testing such as MRI, whole-genome sequencing, DEXA, cardiac testing, biomarkers, and physician review. Our guide to Human Longevity exam cost explains why the value of that model depends less on the test count and more on follow-up ownership.

Biograph and Fountain Life also sit in the premium preventive-health lane, using broader diagnostic stacks and physician-led synthesis. Neko is trying to make a narrower scan-and-review experience faster and more accessible. That can be useful, but a scan is not the same thing as a health plan.

The clean comparison is:

Model	What you buy	Main buyer risk
Public preventive care	Guideline-based checks such as blood pressure, cholesterol, diabetes risk, cancer screening, and age-based risk review	May be slower, narrower, or fragmented
Scan-first preventive model	Faster access to broad data and a clinician conversation	More findings without long-term medical ownership
Premium longevity clinic	Broad diagnostics, physician synthesis, longitudinal follow-up, and sometimes therapeutics	High cost and variable evidence quality

Evidence Boundaries

Preventive medicine is not simply “measure more.” Good screening has to find conditions early enough to improve outcomes, avoid excessive harm, and connect results to action.

The USPSTF A and B recommendations are a useful conservative baseline because they list preventive services with high or moderate net benefit.⁴ The NHS Health Check is another public-health baseline: for eligible adults aged 40 to 74 in England, it focuses on cardiovascular health and risk of heart disease, diabetes, kidney disease, and stroke every five years.⁵

Neither baseline looks like a luxury scan. That is the point. Prevention starts with risk, age, symptoms, family history, blood pressure, cholesterol, diabetes risk, smoking, and guideline-based cancer screening. A scan-first company can add data, but it should not distract from the basics.

Skin scanning is a good example. Neko emphasizes skin mapping and mole storage. That may help monitoring and clinician review. But the USPSTF says evidence is currently insufficient to assess the balance of benefits and harms of clinician visual skin examination for asymptomatic adolescents and adults without signs or symptoms of skin cancer.⁶ That does not mean skin review is bad. It means broad screening claims should be modest.

The Hidden Cost: Follow-Up

Broad scans find things. Some findings matter. Others are benign, uncertain, or likely irrelevant.

The American College of Radiology notes that many incidental findings are unlikely to pose health risks, but that low-risk findings can lead to over-testing and over-treatment when follow-up guidance is weak.⁷ A BMJ umbrella review found that incidental imaging findings vary widely by modality and organ system, and that clinicians and patients need to weigh the pros and cons before ordering imaging and after findings appear.⁸

Neko is not MRI, but the same buyer logic applies to any broad screening product. The medical value is the pathway:

• Who decides whether a finding is urgent?
• Who confirms an abnormal result?
• Does the company arrange referral or only write a letter?
• Can your GP or primary doctor actually use the report?
• What is repeated next year, and why?
• What happens when a result is borderline but not clearly disease?

Our longevity clinic follow-up plan guide is the framework to use here. A scan without follow-up is a snapshot. A scan with clear escalation can become decision support.

Who Might Consider Neko?

Neko may fit buyers who want a lower-cost, clinician-reviewed baseline and understand its limits. It may be more appropriate for someone who:

• wants a structured preventive snapshot but is not ready for a premium program;
• already has a GP or primary doctor who can integrate results;
• wants skin, cardiovascular, metabolic, and blood-marker review;
• is comfortable with the possibility of uncertain findings;
• sees the scan as a starting point, not a clean bill of health.

It is less likely to be enough for someone with symptoms, strong family history, known genetic risk, complex cardiometabolic disease, prior cancer, abnormal previous imaging, or a need for physician-led medication and specialist coordination. Those buyers may need targeted medical care, not a consumer scan.

Buyer Checklist Before Booking

Before joining a waitlist or paying, ask these questions:

1. What exact tests are included in my location?
2. Is the price public and written for my city?
3. Who interprets the results: doctor, nurse, specialist, or algorithm plus clinician?
4. Which findings trigger same-day escalation?
5. Which findings need confirmatory testing?
6. Are referrals, referral letters, or specialist introductions included?
7. Will my GP or doctor receive usable records?
8. Can I export my data?
9. What happens after a borderline result?
10. What should change in the next 90 days?

The strongest answer is concrete. “You receive your results” is not enough. The buyer wants to know who owns the next step.

Bottom Line

Neko Health is interesting because it lowers the entry price for a polished preventive scan. The UK offer is public: GBP 299 for a one-hour scan and clinician consultation. The New York story is promising but should be treated carefully: Neko’s official page confirms New York as its first North American clinic and says it is coming in 2026, while Vogue Business reported an expected roughly USD 500 price from sources close to the company.¹³ Neko’s 2025 Series B release also shows scale: USD 260 million raised, 10,000 scans completed, and more than 100,000 people on the waiting list at that time.⁹

For buyers, the rule is simple. Do not judge a scan by how futuristic it feels. Judge it by what happens after the scan.

If the result creates a clear action plan, appropriate referrals, and useful records for your doctor, a scan-first model can be a practical entry point. If it creates more data without medical ownership, even an affordable scan can become an expensive question mark.

Footnotes

1. Vogue Business. “Neko Wants to Be the ‘Affordable Luxury’ of Longevity.” Published June 15, 2026. Retrieved July 4, 2026. https://www.vogue.com/article/neko-wants-to-be-the-affordable-luxury-of-longevity ↩ ↩²

2. Neko Health. “Neko Health Scan.” Browser-verified July 4, 2026. https://www.nekohealth.com/gb/en/health-scan ↩ ↩² ↩³ ↩⁴

3. Neko Health. “New York City.” Browser-verified July 4, 2026. https://www.nekohealth.com/us/en/locations/nyc/nyc ↩ ↩²

4. United States Preventive Services Taskforce. “A and B Recommendations.” Retrieved July 4, 2026. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations ↩

5. NHS. “NHS Health Check.” Retrieved July 4, 2026. https://www.nhs.uk/tests-and-treatments/nhs-health-check/ ↩

6. United States Preventive Services Taskforce. “Skin Cancer: Screening.” Final Recommendation Statement, April 18, 2023. Retrieved July 4, 2026. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/skin-cancer-screening ↩

7. American College of Radiology. “Incidental Findings.” Retrieved July 4, 2026. https://www.acr.org/Clinical-Resources/Incidental-Findings ↩

8. O’Sullivan JW, et al. “Prevalence and outcomes of incidental imaging findings: umbrella review.” BMJ. 2018. Retrieved July 4, 2026. https://pubmed.ncbi.nlm.nih.gov/29914908/ ↩

9. Neko Health. “Neko Health raises $260m Series B.” Published January 23, 2025. Browser-verified July 4, 2026. https://www.nekohealth.com/gb/en/press/neko-health-raises-260m-series-b ↩